Advances of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer
10.16139/j.1007-9610.2024.06.13
- VernacularTitle:抗体药物偶联物在晚期三阴性乳腺癌治疗中的研究进展
- Author:
Yiwei TONG
;
Xiaosong CHEN
- Publication Type:Journal Article
- From:
Journal of Surgery Concepts & Practice
2024;29(6):533-536
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer (TNBC) is insensitive to endocrine therapy or anti-human epidermal growth factor receptor(HER)-2 targeted therapy due to its lack of expression of hormone receptors and HER-2. Antibody-drug conjugates(ADCs) recognize specific antigens on the surface of cancer cells through specific antibodies, form antigen-antibody complexes that are then internalized, and subsequently release their payloads to kill cancer cells, which offering a novel therapeutic option for metastatic TNBC. Currently, ADCs undergoing research and clinical application in metastatic TNBC include sacituzumab govitecan, datopotamab deruxtecan (Dato-DXd), SKB264, and trastuzumab deruxtecan (T-DXd). This article summarized the targets and structural characteristics of ADCs in metastatic TNBC, systematically reviewed the efficacy and safety of ADCs from relevant clinical studies, and discussed the issues of the clinical application of ADCs.
